FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Okajima Masatsune 2. Issuer Name and Ticker or Trading Symbol MEDICINOVA INC [ MNOV ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
VP and Head of Japanese Office
(Last)          (First)          (Middle)
C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 300
3. Date of Earliest Transaction (MM/DD/YYYY)
2/28/2019
(Street)
LA JOLLA, CA 92037
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/28/2019     M    35700   A $7.34   189280   D    
Common Stock   2/28/2019     M    85000   A $2.54   274280   D    
Common Stock   2/28/2019     M    63750   A $2.46   338030   D    
Common Stock   2/28/2019     M    80000   A $4.10   418030   D    
Common Stock   2/28/2019     M    42500   A $4.10   460530   D    
Common Stock   2/28/2019     M    105000   A $2.64   565530   D    
Common Stock   2/28/2019     M    15000   A $3.24   580530   D    
Common Stock   2/28/2019     M    105000   A $3.09   685530   D    
Common Stock   2/28/2019     M    30000   A $3.91   715530   D    
Common Stock   2/28/2019     M    120000   A $3.91   835530   D    
Common Stock   2/28/2019     M    100000   A $6.10   935530   D    
Common Stock   2/28/2019     M    105000   A $7.00   1040530   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   $7.34   2/28/2019     M         35700      (1) 1/28/2020   Common Stock   37500   $0   0   D    
Employee Stock Option (Right to Buy)   $2.54   2/28/2019     M         85000      (2) 7/12/2021   Common Stock   85000   $0   0   D    
Employee Stock Option (Right to Buy)   $2.46   2/28/2019     M         63750      (3) 8/2/2021   Common Stock   63750   $0   0   D    
Employee Stock Option (Right to Buy)   $4.10   2/28/2019     M         80000      (4) 5/12/2023   Common Stock   80000   $0   0   D    
Employee Stock Option (Right to Buy)   $4.10   2/28/2019     M         42500      (5) 5/12/2023   Common Stock   42500   $0   0   D    
Employee Stock Option (Right to Buy)   $2.64   2/28/2019     M         105000      (6) 12/11/2023   Common Stock   105000   $0   0   D    
Employee Stock Option (Right to Buy)   $3.24   2/28/2019     M         15000      (7) 12/3/2024   Common Stock   15000   $0   0   D    
Employee Stock Option (Right to Buy)   $3.09   2/28/2019     M         105000      (8) 1/6/2025   Common Stock   105000   $0   0   D    
Employee Stock Option (Right to Buy)   $3.91   2/28/2019     M         30000      (9) 1/6/2026   Common Stock   30000   $0   0   D    
Employee Stock Option (Right to Buy)   $3.91   2/28/2019     M         120000      (10) 1/6/2026   Common Stock   120000   $0   0   D    
Employee Stock Option (Right to Buy)   $6.10   2/28/2019     M         100000      (11) 1/17/2027   Common Stock   100000   $0   0   D    
Employee Stock Option (Right to Buy)   $7.00   2/28/2019     M         105000      (12) 1/5/2028   Common Stock   105000   $0   0   D    

Explanation of Responses:
(1)  The option vested over a period of 4 years in equal monthly installments from the 1/28/2010 date of grant and is now fully vested.
(2)  The option vested over a period of 4 years in equal monthly installments from the 7/13/2011 date of grant and is now fully vested.
(3)  The option was granted on 8/3/2011, was subject to vesting based on achievement of performance criteria and vested in full on 6/14/2012.
(4)  The option was granted on 5/13/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/2/2013.
(5)  The option vested over a period of 4 years in equal monthly installments from the 5/13/2013 date of grant and is now fully vested.
(6)  The option was granted on 12/12/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/4/2014.
(7)  The option vested over a period of 3 years in equal monthly installments from the 12/4/2014 date of grant and is now fully vested.
(8)  The option was granted on 1/7/2015, was subject to vesting based on achievement of performance criteria and vested in full on 1/7/2016.
(9)  The option vested over a period of 3 years in equal monthly installments from the 1/7/2016 date of grant and is now fully vested.
(10)  The option was granted on 1/7/2016, was subject to vesting based on achievement of performance criteria and vested in full on 1/18/2017.
(11)  The option was granted on 1/18/2017, was subject to vesting based on achievement of performance criteria and vested in full on 1/6/2018.
(12)  The option was granted on 1/6/2018, was subject to vesting based on achievement of performance criteria and vested in full on 1/15/2019.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Okajima Masatsune
C/O MEDICINOVA, INC.
4275 EXECUTIVE SQUARE, SUITE 300
LA JOLLA, CA 92037


VP and Head of Japanese Office

Signatures
/s/ Masatsune Okajima 3/4/2019
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Medicinova Charts.
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Medicinova Charts.